Literature DB >> 20703833

Loss and preservation of beta-cell function: two treatment regimes targeting T or B lymphocytes.

Anette-G Ziegler1, Markus Walter.   

Abstract

Year:  2010        PMID： 20703833     DOI： 10.1007/s11892-010-0141-3

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  4 in total

1.  Disengaging the IL-2 receptor with daclizumab enhances IL-7-mediated proliferation of CD4(+) and CD8(+) T cells.

Authors:  P Monti; C Brigatti; A K Heninger; M Scirpoli; E Bonifacio
Journal:  Am J Transplant       Date:  2009-09-25       Impact factor: 8.086

2.  Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.

Authors:  C R Stiller; J Dupré; M Gent; M R Jenner; P A Keown; A Laupacis; R Martell; N W Rodger; B von Graffenried; B M Wolfe
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

3.  Prevention of diabetes: effect of mycophenolate mofetil and anti-CD25 on onset of diabetes in the DRBB rat.

Authors:  Figen Ugrasbul; Wayne V Moore; Pei Ying Tong; Karen L Kover
Journal:  Pediatr Diabetes       Date:  2008-05-21       Impact factor: 4.866

4.  B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice.

Authors:  D V Serreze; H D Chapman; D S Varnum; M S Hanson; P C Reifsnyder; S D Richard; S A Fleming; E H Leiter; L D Shultz
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.